News & Views

  • Acquisition Expands Drug Discovery Capabilities
    Dr Richard Weaver, Founder & CEO of Xenogesis (right) with Dr Simon Hirst, Founder & CEO of Sygnature

Acquisition Expands Drug Discovery Capabilities

Oct 14 2020 Read 191 Times

With the acquisition of XenoGesis, the UK’s largest independent laboratory-based CRO specialising in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and interpretation, Sygnature has effectively doubled the size of its DMPK department, adding new skills and capabilities to its service offering. Both companies are located at BioCity, Nottingham.

Since its inception in 2011, XenoGesis has achieved a strong track record of success through its focus on high quality science and clinical considerations from the outset of a drug discovery project, resulting in the early prediction of PK and likely human dosage potentially enabling more successful candidate molecules.

Dr Simon Hirst, CEO and Founder at Sygnature, said: “Our ultimate mission at Sygnature is to help create life-changing drugs for patients that have made it through the drug discovery and development process and we recognise the central role that DMPK plays in that journey.

“Sygnature is not growing for the sake of growing. We believe that truly integrated drug discovery is the best possible way forward in bringing novel efficacious drug candidates to man; that having teams working together across every discipline involved in a research project, sharing ideas and resolving challenges, will produce the sparks of innovation and high-quality science needed to enable success.

Dr Richard Weaver, CEO and Founder at XenoGesis added:

“Sygnature and XenoGesis have always had a superb working relationship and been closely aligned in our culture and aspirations. From the start, both companies have focused on world-class science, insightful data interpretation, and creating genuine partnerships with our customers.

“Therefore, this step feels like a very natural one, and we are very excited about what we can accomplish together in helping accelerate our customers’ projects towards the clinic. My team and I are looking forward to joining forces with Sygnature.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment





Digital Edition

Measurement Analysis China 2021 Buyers Guide

November 2020

The following Buyers’ Guide has been produced by International Labmate Ltd. International Labmate have been publishing magazines for over 46 years. We now publish 9 laboratory, environmental and...

View all digital editions

Events

Expomed Eurasia - NEW DATES

Nov 05 2020 Istanbul, Turkey

Pharma Asia - NEW DATES

Nov 10 2020 Karachi, Pakistan

JASIS 2020

Nov 11 2020 Chiba City, Japan

International Solid Waste Management Summit

Nov 12 2020 Shanghai, China

SETAC North America

Nov 15 2020 Virtual event

View all events